SMSebastian Moreno‐Castro

Sebastian Moreno‐Castro

*This is an algorithmically generated author record based on publicly available information.

Sebastian Moreno‐Castro has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Allergen Immunotherapy and 36‐Month Allergic Respiratory Disease Trajectories: A Target‐Trial

    by Víctor Gonzalez‐Uribe, Sebastian Moreno‐Castro, Viviana Cardoso‐Perez, Diego A Mares‐Mateos, Mariel Paez‐Reyes, Jimena Prieto‐Gomez, Ricardo Martinez‐Tenopala, Paola de Baro Alvarez

    Background: Allergen immunotherapy (AIT) may modify allergic respiratory disease, but its association with progression and remission in routine practice remains uncertain. Materials and Methods: We emulated a target trial in a single‐center retrospective cohort at AlergiaMx, Mexico City, using data from 2020 to 2025. We compared sublingual allergen immunotherapy initiation within a 14‐day grace period with non‐initiation among AIT‐eligible patients. Follow‐up extended up to 36 months, and propensity‐score overlap weighting addressed baseline confounding. Results: Among 2,713 patients, 1,971 initiated AIT and 742 did not. Weighted disease worsening was 46.3% versus 63.6% (relative risk [RR] 0.73, 95% confidence interval [CI] 0.65–0.82), and sustained progression was 8.4% versus 17.0% (RR 0.49, 95% CI 0.35–0.69). At 36 months, clinical remission was 47.0% versus 18.3% (RR 2.57, 95% CI 1.93–3.43), and treatment‐associated remission was 31.7% versus 5.8% (RR 5.44, 95% CI 3.23–9.16). Longitudinal differences favored AIT for asthma control, quality of life, and fractional exhaled nitric oxide. Discussion: AIT initiation was associated with less worsening, greater remission, and favorable clinical and inflammatory trajectories over 36 months. These observational findings do not establish a causal disease‐modifying effect; residual confounding and differential follow‐up remain possible.

  • Early and longitudinal response to sublingual immunotherapy across pediatric allergic multimorbidity patterns: A 3‐year real‐world cohort study

    by Victor Gonzalez‐Uribe, Jimena Prieto‐Gomez, Sebastian Moreno‐Castro, Ricardo Martinez‐Tenopala, Maria Julia Rendon‐Salazar, Tamara Hernandez‐Hernandez, Zaira Selene Mojica‐Gonzalez, Paola de Baro‐Alvarez

    Background: The timing of clinically meaningful benefit after pediatric sublingual immunotherapy (SLIT) across allergic multimorbidity patterns remains uncertain. We evaluated early and longitudinal response to SLIT in routine care. Methods: This retrospective longitudinal cohort included patients aged 3–17 years who received individualized liquid‐drop SLIT and met prespecified adherence and treatment‐persistence criteria. Assessments were performed at baseline and months 6, 12, 18, 24, and 36. The primary outcome was achievement of the Pediatric Asthma Quality of Life Questionnaire (PAQLQ) minimal clinically important difference (MCID; increase ≥0.5 points) at month 6. Results: Among 1208 patients, 1095 had asthma and 954 allergic rhinitis. Overall, 666/1095 (60.8%) achieved month‐6 PAQLQ MCID: 515/671 (76.8%) with asthma plus allergic rhinitis (Asthma+AR), 103/254 (40.6%) with allergic asthma without AR, and 48/170 (28.2%) with asthma, AR, and atopic dermatitis (Asthma+AR + AD). Compared with allergic asthma without AR, adjusted odds of response were higher for Asthma+AR (adjusted odds ratio 4.73, 95% CI 3.47–6.45) and lower for Asthma+AR + AD (0.52, 95% CI 0.34–0.80). By month 36, mean PAQLQ increased by 1.42 points, rhinitis‐related quality‐of‐life scores decreased by 1.89 points, FeNO decreased by 15.7 ppb, and prescribed inhaled corticosteroid dose decreased by 92.6%. Conclusion: Early response to pediatric SLIT differed across clinical allergic multimorbidity patterns, although outcomes continued to improve through 36 months in this selected adherent and treatment‐persistent cohort. image